Surmodics Reports First Quarter Fiscal 2021 Results

Go back to Surmodics Reports First Quarter Fiscal 2021 Results

SurModics (SRDX) Tops Q1 EPS by 7c

February 9, 2021 7:43 AM EST

SurModics (NASDAQ: SRDX) reported Q1 EPS of ($0.02), $0.07 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $22.3 million versus the consensus estimate of $22.37 million.

The entire Surmodics team is wholeheartedly pleased with the results of our TRANSCEND clinical trial, which... More